B-lineage monoclonal antibodies (anti-CD20: rituximab, ofatumumab, and obinutuzumab; anti-CD38: isatuximab and daratumumab; anti-CD30: brentuximab vedotin; anti-CD52: alemtuzumab; anti-CD269: belantamab mafodotin; or anti-CD319: elotuzumab) were used in three studies in CLL (54, 59, 66), two in MM (68, 91), and seven in NHL (110, 113, 122, 124, 127, 128, 134) as monotherapy. Here, SLAMF7 is linked to non-Hodgkin lymphoma.